ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Avance Clinical Launches Diversity in STEM Scholarships Across Australia and North America

ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch of its new Diversity in STEM Scholarships, a global initiative designed to support women and minority-group students pursuing careers in science, technology, engineering, and mathematics (STEM). The program includes dedicated intakes in Australia and the broader Asia-Pacific region, as well as North America, reinforcing the company’s commitment to equity and inclusion in clinical research.

Avance Clinical is focused on breaking down barriers and fostering opportunity for the next generation of scientific leaders. The scholarships provide both financial assistance and hands-on industry experience to help promising students launch meaningful STEM careers that contribute to better patient health outcomes.

Scholarship Overview

Two annual scholarships will be awarded:

  • One for the APAC intake (AUD $5,000)
  • One for the North America intake (USD $5,000)

In addition to university financial support, scholarship recipients may be offered the opportunity to complete an internship at Avance Clinical, gaining valuable experience within a global clinical research organization.

Who Can Apply
Undergraduate students - or those recently accepted into an undergraduate program - who identify as women or members of a minority group and are pursuing a STEM-related degree. Eligible disciplines include:

  • Life Sciences (biology, biotechnology, biochemistry, genetics, pharmacology)
  • Clinical Research/Clinical Sciences
  • Medical Sciences (medicine, nursing, public health)
  • Data and Technology in Health (biostatistics, bioinformatics, data science, biomedical engineering)

Application Deadlines

  • APAC intake: 10 January 2026
  • North America intake: 10 March 2026

Applicants are required to submit a 300-word essay outlining their interest in STEM and how the scholarship will support their career goals. Final selections will be made by Avance Clinical’s Senior Leadership Team. Apply Now

CEO Mark Harvill: Supporting Diverse Talent in Clinical Research

“We believe that a diverse talent pipeline is essential for driving innovation and excellence in clinical research,” said Mark Harvill, Chief Executive Officer of Avance Clinical.

“These scholarships reflect our company’s values and our responsibility to invest in diverse talent. By providing both financial support and, when possible, practical experience, we aim to help exceptional students from all backgrounds to build careers that will contribute to the strength of clinical research.”

How to Apply

Eligible students can apply via the website, Avance Clinical Diversity in STEM Scholarships, selecting either the APAC or North America intake depending on their region of study. Please direct questions to scholarships@avancecro.com.

About Avance Clinical

Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia and North America for biotechs. The company has won multiple Frost & Sullivan CRO Market Leadership and Customer Value Leadership Awards. With over 30 years of experience and deep expertise across more than 250 indications, Avance Clinical provides services from pre-clinical consulting to late phase trials, supported by best-in-class regulatory, clinical and operational expertise.

Find Out More:


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.10
-0.44 (-0.20%)
AAPL  272.99
-1.12 (-0.41%)
AMD  208.26
+0.68 (0.33%)
BAC  54.95
-0.38 (-0.70%)
GOOG  305.35
-3.97 (-1.28%)
META  652.56
+5.05 (0.78%)
MSFT  474.52
-0.30 (-0.06%)
NVDA  176.98
+0.69 (0.39%)
ORCL  188.56
+3.64 (1.97%)
TSLA  477.68
+2.37 (0.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.